.Pharmacolibrary.Drugs.ATC.J.J04AK05 .Pharmacolibrary.Drugs.ATC.J.J04AK05| name: | Bedaquiline |
| ATC code: | J04AK05 | route: | oral |
| n-compartments | 3 |
Bedaquiline is a diarylquinoline antimycobacterial agent used for the treatment of multidrug-resistant tuberculosis (MDR-TB). It acts by inhibiting the mycobacterial ATP synthase enzyme and has been approved for use in combination therapy for MDR-TB in adults and some pediatric populations. Bedaquiline is currently approved by regulatory agencies including the FDA and EMA.
Population pharmacokinetics in adult patients with multidrug-resistant pulmonary tuberculosis, generally healthy except for TB, mixed sex, studied after oral administration.
Zhu, H, et al., & Lu, Y (2021). Population pharmacokinetics of bedaquiline in patients with drug-resistant TB. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 25(12) 1006–1012. DOI:10.5588/ijtld.21.0158 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34886931
Tanneau, L, et al., & Svensson, EM (2022). Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline. Clinical pharmacokinetics 61(8) 1177–1185. DOI:10.1007/s40262-022-01133-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35668346
Maloney, SE, et al., & Hickey, AJ (2023). Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration. Pharmaceuticals (Basel, Switzerland) 16(5) –. DOI:10.3390/ph16050729 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37242512